urea has been researched along with Hyperphosphatemia in 6 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Indices of urea reduction ratio (URR), anemia, hyperphosphatemia, and predialysis BP (BP) control in a subgroup of all patients on LOH for at least 1 yr since 2004 were compared with age, sex, and diabetes-matched controls undergoing conventional duration HD." | 3.75 | Ten years experience of in-center thrice weekly long overnight hemodialysis. ( Geddes, CC; Jardine, AG; Latta, C; Narasinghan, E; Oluwaseun, O; Padmanabhan, N; Powell, JR; Tortolano, J; Woo, YM, 2009) |
| "The control of hyperphosphatemia is an unmet need in dialysis care." | 2.77 | Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis. ( Dorigo, DM; Ruzany, F; Sampaio, MS; Suassuna, JH, 2012) |
| "Hyperphosphatemia is highly prevalent in hemodialysis (HD) and peritoneal dialysis (PD) patients and is a major risk factor for cardiovascular mortality." | 2.46 | Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. ( Kuhlmann, MK, 2010) |
| "Hyperphosphatemia is an independent risk factor for mortality in ESRD, but factors regulating phosphate clearance on peritoneal dialysis (PD) are incompletely understood." | 1.35 | Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics. ( Badve, SV; Burns, KD; Knoll, GA; McCormick, BB; Zimmerman, DL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| López-Guerra, EA | 1 |
| Rodríguez-García, VH | 1 |
| Rodríguez-Castellanos, FE | 1 |
| Badve, SV | 1 |
| Zimmerman, DL | 1 |
| Knoll, GA | 1 |
| Burns, KD | 1 |
| McCormick, BB | 1 |
| Powell, JR | 1 |
| Oluwaseun, O | 1 |
| Woo, YM | 1 |
| Padmanabhan, N | 1 |
| Narasinghan, E | 1 |
| Latta, C | 1 |
| Tortolano, J | 1 |
| Jardine, AG | 1 |
| Geddes, CC | 1 |
| Kuhlmann, MK | 1 |
| Ivanov, M | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Grujic Milanovic, J | 1 |
| Jovovic, D | 1 |
| Miloradovic, Z | 1 |
| Sampaio, MS | 1 |
| Ruzany, F | 1 |
| Dorigo, DM | 1 |
| Suassuna, JH | 1 |
1 review available for urea and Hyperphosphatemia
| Article | Year |
|---|---|
Phosphate elimination in modalities of hemodialysis and peritoneal dialysis.
Topics: Anticoagulants; Ascitic Fluid; Cardiovascular Diseases; Combined Modality Therapy; Creatinine; Diffu | 2010 |
1 trial available for urea and Hyperphosphatemia
| Article | Year |
|---|---|
Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis.
Topics: Adult; Creatinine; Dialysis Solutions; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; M | 2012 |
4 other studies available for urea and Hyperphosphatemia
| Article | Year |
|---|---|
Determination of peritoneal phosphate transport as a tool for controlling serum phosphorus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biological Transport; Creatinine; Cross-Sectional Studie | 2014 |
Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics.
Topics: Adult; Aged; Creatinine; Cross-Sectional Studies; Female; Humans; Hyperphosphatemia; Kidney Failure, | 2008 |
Ten years experience of in-center thrice weekly long overnight hemodialysis.
Topics: Adult; Aged; Anemia; Blood Pressure; Case-Control Studies; Erythropoietin; Female; Hemoglobins; Huma | 2009 |
Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Hemodynamics; Hyp | 2011 |